Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus BioSciences (NASDAQ: CHRS ) has shed its marketed biosimilar drugs, now only markets the branded drug Loqtorzi (toripalimab), and is focusing on development of its clinical pipeline. When I last covered the name in May 2024, I rated CHRS aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Di ...